EPISODE · May 25, 2026 · 17 MIN
FDA Approves First Non-Antipsychotic Drug For Dementia Agitation, Reshaping Treatment Options
from 1nessAgency Insights
On April 30, 2026, the FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for a new indication: treating agitation associated with Alzheimer's disease dementia in adults [1]. The approval is a first of its kind , no non-antipsychotic drug has ever carried this indicati
What this episode covers
On April 30, 2026, the FDA approved Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) for a new indication: treating agitation associated with Alzheimer's disease dementia in adults [1]. The approval is a first of its kind , no non-antipsychotic drug has ever carried this indicati
NOW PLAYING
FDA Approves First Non-Antipsychotic Drug For Dementia Agitation, Reshaping Treatment Options
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m